Abbott (NYSE:ABT) today unveiled a new feature within its FreeStyle Libre app for continuous glucose monitoring (CGM).
The FreeStyle Libre 3 system is the most accurate 14-day continuous glucose monitor1, with readings sent directly to a smartphone every minute.2 Designed for access and affordability, the FreeStyle ...
Just a short while after securing a CE Mark for its second generation device, Abbott has been granted FDA clearance for FreeStyle LibreLink, a companion mobile app for its 10 to 14-day CGM. The launch ...
Abbott Laboratories’ ABT next-generation FreeStyle Libre 3 system was recently approved by the FDA for diabetes patients aged four years and older. The FreeStyle Libre 3 system will be priced ...
Patients with type 2 diabetes (T2D) who had been using insulin an average of 8 years and had mean glycated hemoglobin (A1C) levels of 8.9% were able to bring their levels down 0.9% after 3 months, ...
The FreeStyle Libre 3 system is the latest generation in Abbott (ABT)'s FreeStyle Libre portfolio – the most prescribed and affordable integrated continuous glucose monitoring (iCGM) system in the ...
ABBOTT PARK, Ill., Sept. 3, 2014 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that it has received CE Mark (Conformite Europeenne) for its FreeStyle ® Libre Flash Glucose Monitoring System, a ...
SAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care, Inc (TNDM). (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company today announced the Tandem t:slim X2™ insulin pump with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback